CLAIMS

1. Use of lurbinectedin in the manufacture of a medicament for the treatment of extensive stage small cell lung cancer (ES-SCLC), wherein the lurbinectedin is to be administered to a patient as part of a combination of lurbinectedin and atezolizumab; wherein lurbinectedin is to be administered at a dose of 3.2 mg/m^2 and atezolizumab is to be administered at a dose of 1200mg; and wherein lurbinectedin and atezolizumab are administered on day 1 of a 21 day cycle.

2. The use according to claim 1 wherein lurbinectedin and atezolizumab are to be administered concurrently, separately or sequentially.

3. The use according to any preceding claim, wherein atezolizumab is to be administered initially, immediately followed by lurbinectedin.

4. The use according to any preceding claim, wherein multiple administrations of either lurbinectedin, or atezolizumab, or both, are given.

5. The use according to any preceding claim, wherein lurbinectedin is to be administered by intravenous infusion.

6. The use according to any preceding claim, wherein lurbinectedin is to be administered with an infusion time of up to 24 hours, 1 to 12 hours, 1 to 6 hours and most preferably 1 hour.

7. The use according to any preceding claim, wherein atezolizumab is to be administered by subcutaneous route.

8. The use according to any preceding claim, wherein atezolizumab is to be administered by intravenous route.

9. The use according to claim 7 or claim 8, wherein atezolizumab is to be administered with an infusion time of 1 hour; or of 30 minutes for the second and subsequent infusions.

10. The use according to any preceding claim, wherein the method further comprises administration of granulocyte-colony stimulating factor (G-CSF).

11. The use according to claim 10 when G-CSF is to be administered on day 1 of a 21 day cycle.

12. The use according to claim 11, wherein the patient receives primary prophylaxis with G-CSF starting 24-72 hours after Day 1 of each cycle, and for five days.

13. The use according to any preceding claim comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,

13, 14, 15, 16, 17, 18, 19, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more cycles.

14. The use according to any preceding claim, wherein the treatment results in reduction in tumour size.

15. The use according to any preceding claim, wherein the treatment results in delay in growth of tumour.

16. The use according to any preceding claim, wherein the treatment results in prolongation of life of the patient.

17. The use according to any preceding claim, wherein the treatment results in delay in disease progression

18. The use according to any preceding claim, wherein the treatment results in remission.

19. A method of inhibiting cancer cell growth, comprising contacting cancer cells with a combination of lurbinectedin and atezolizumab; wherein said cancer cells are extensive stage small cell lung cancer (ES-SCLC) cells.

20. A kit comprising lurbinectedin, together with instructions according to any preceding claim for the combination use of lurbinectedin and atezolizumab in the treatment of extensive stage small cell lung cancer (ES-SCLC).